Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“To clarify this question, we analyzed BCR-ABL activity in imatinib-treated quiescent CML cells using Ki-67 negativity as a marker of quiescence (37).”
MethodFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 3×
“Newly diagnosed patients with chronic phase CML have an almost 90% chance of being alive at 60 months after diagnosis (2).”
BackgroundSelf-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“Enhanced expression of the drug efflux pumps breast cancer resistance protein (10) and P-glycoprotein (11) in CML stem cells may reduce sensitivity to imatinib by lowering intracellular imatinib concentrations (12–15).”
BackgroundAC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 2×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundSelf-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218 · cited 4×
“Those whose disease is undetectable by RT-PCR usually experience recurrence of active leukemia when imatinib therapy is discontinued (4, 5), which indicates that leukemic cells persist in most patients even when the disease burden is reduced below detectable limits.”
BackgroundInfluentialGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181 · cited 6×
“In accord with previous reports (19), we observed that primitive noncycling BCR-ABL–positive cells”
BackgroundResultInfluential
Cited by
Items 601–700 of 799
Lessons to cancer from studies of leukemia and hematopoiesis
Brown, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.993915 · Cited by 6
“CML-LSCs are resistant to tyrosine kinase inhibitors, despite the expression of BCR-ABLp220 protein (Graham et al., 2002; Corbin et al., 2011).”
BackgroundMuselli, F., Mourgues, L., Rochet, N., Nebout, M., Guerci‐Bresler, A., Verhoeyen, E., Krug, A., Legros, L., Peyron, J., & Mary, D. (2023) · Cancers · doi:10.3390/cancers15030995 · Cited by 3
“ALX also affected CML stem/progenitor cells that represent a clinical issue as they are resistant to Tyrosine Kinase Inhibitors (TKIs) that target the BCR::ABL1 oncogenic driver of CML. Interestingly, ALX showed synergistic cell death effects when combined with TKIs from three generations.”
BackgroundInfluentialMalighetti, F., Arosio, G., Manfroni, C., Mauri, M., Villa, M., Manghisi, B., Inzoli, E., Rindone, G., Zambrotta, G. P. M., Civettini, I., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000852 · Cited by 3
Tasneem, A., Sharma, A. K., Syed, M. A., & Dohare, R. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00614-2 · Cited by 3
“However, unlike their normal counterparts, CML_P requires BCR-ABL tyrosine kinase activity for cytokine-independent survival and proliferation [13].”
Human CML stem cells insensitive to imatinib even when BCR–ABL is inhibited
Hutchinson, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.9 · Cited by 3
Targeting BCR-ABL and JAK2 in Ph+ ALL
Hantschel, O. D. (2015) · Blood · doi:10.1182/blood-2014-12-617548 · Cited by 3
Response: too much BCR-ABL to live on, but too little BCR-ABL to die on?
Burchert, A., Neubauer, A., & Hochhaus, A. (2012) · Blood · doi:10.1182/blood-2012-01-405373 · Cited by 5
Breast Cancer Heterogeneity: Need to Review Current Treatment Strategies
Malik, F. A., Körkaya, H., Clouthier, S. G., & Wicha, M. S. (2012) · Current Breast Cancer Reports · doi:10.1007/s12609-012-0093-5 · Cited by 3
Zhang, N., Huang, L., Tian, J., Chen, X., Ke, F., Zheng, M., Xu, J., & Wu, L. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.11.002 · Cited by 3
Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia
Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_4 · Cited by 4
Self-citationAfreen, S. (2013) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s14-001 · Cited by 3
“This is due to the fact that these drugs do not eliminate the Philadelphia positive CML stem cells [9,13-20].”
BackgroundZhang, C., Zhang, X., Yang, S., & Chen, X.-H. (2017) · Oncology Letters · doi:10.3892/ol.2017.5686 · Cited by 3
“No change was observed for caspase 8 (Fig.”
Can increased immunogenicity in chronic myeloid leukemia improve outcomes?
Chan, O., Talati, C., Sweet, K. L., & Pinilla-Ibarz, J. A. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1588105 · Cited by 3
“TKIs are not very effective against the quiescent CML stem cells (LSCs), which are shown to be independent of BCR-ABL activity for survival [11,12].”
BackgroundCombination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
Muselli, F., Mourgues, L., Morcos, R., Rochet, N., Nebout, M., Guerci‐Bresler, A., Faller, D. V., William, R., Mhaidly, R., Verhoeyen, E., et al. (2021) · Cancers · doi:10.3390/cancers13071693 · Cited by 3
“Indeed, it is well known that although the bulk of chronic myeloid leukemia cells are very sensitive to BCR-ABL inhibitors, CML LSCs are not dependent on BCR-ABL kinase activity to survive [11,12].”
BackgroundMolecular Biology and Cytogenetics of Chronic Myeloid Leukemia
Konopleva, M. Y., Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_4 · Cited by 3
Self-citationTolland, M., Ross, D. M., White, D. L., Hughes, T. P., & Pagani, I. S. (2025) · Cancers · doi:10.3390/cancers17183033 · Cited by 2
“Moreover, most patients who do respond to treatment require ongoing TKI therapy to prevent disease progression and relapse arising from residual CML stem/progenitor cells that are not eradicated by TKIs [14].”
Turner, K. A., Chen, M., Rothe, K., Forrest, D. L., & Jiang, X. (2025) · Cells · doi:10.3390/cells14191565 · Cited by 2
The Influences of RARγ on the Behavior of Normal and Cancer Stem Cells
Brown, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031291 · Cited by 2
“The tyrosine kinase inhibitor imatinib is used to treat CML and LSCs were insensitive to this agent when treated in vitro, despite inhibition of the tyrosine kinase activity of BCR-ABL fusion oncogene [4,5].”
Jo, T., Shioya, H., Tominaga, H., Sakai, T., Hayashi, S., Matsuzaka, K., Kaneko, Y., Matsuo, M., & Taguchi, J. (2020) · Case Reports in Oncology · doi:10.1159/000508997 · Cited by 2
Kherbouche, N., Helal, M., Chekroun, A., & Lakmeche, A. (2020) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/2020038 · Cited by 2
Liao, F., Chen, Y., Wu, Q., Wen, J., Chen, X., Wang, W., Xu, D., & Liu, M. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.029 · Cited by 2
CXCR4 Antagonists for the Treatment of CML
Agarwal, A., O’Hare, T., & Deininger, M. W. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1960-0_18 · Cited by 2
Self-citationPang, L. K., Huang, M.-F., Gingold, J. A., Pena, M., Zhao, R., & Lee, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85767-3.00004-9 · Cited by 3
Yang, C., Cui, X., Xu, L., Zhang, Q., Tang, S., Zhang, M., & Xie, N. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17500 · Cited by 2
Benjamin, E. S. B., Vinod, E., Illangeswaran, R. S. S., Rajamani, B. M., Vidhyadharan, R. T., Bagchi, A., Maity, A., Mohan, A., Parasuraman, G., Amirtham, S. M., et al. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111067 · Cited by 2
Tsukahara, F., & Maru, Y. (2017) · Springer eBooks · doi:10.1007/978-981-10-3332-2_2 · Cited by 2
Novel signaling axis in CML-initiating cells
Zhang, C. C. (2014) · Blood · doi:10.1182/blood-2014-03-560359 · Cited by 2
IL-3 Receptor Alpha Chain is a Biomarker and a Therapeutic Target of Myeloid Neoplasms
Testa, U., & Castelli, G. (2016) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000274 · Cited by 2
Chronic Myeloid Leukaemia – The Choice of Therapy and Future Perspectives
Carella, A. M., Dellepiane, C., Lovera, D., Ibatici, A., Ghiggi, C., Carella, A., & Beltrami, G. (2015) · European Oncology & Haematology · doi:10.17925/eoh.2015.11.01.25 · Cited by 2
Casolari, D. A., & Melo, J. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_7 · Cited by 4
Gorji, M., Kiani, A. A., Shahsavar, F., Ahmadi, K., Nazarabad, V. H., & Bahmani, B. (2016) · International Journal of Applied and Basic Medical Research · doi:10.4103/2229-516x.192591 · Cited by 2
“[1,2] Unlike acute leukemias, these neoplasms do not show disruption in cell maturation and differentiation, and thus, a high count of differentiated cells of myeloid series is observed in bone marrow and peripheral blood of patients.[3,4] Moreover, increase in immature and mature granulocytes (with blast count <10%)…”
BackgroundDemirel, Ö., Balló, O., Reddy, P. N. G., Vakhrusheva, O., Zhang, J., Eichler, A., Fernandes, R. G., Badura, S., Serve, H. L., & Brandts, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180401 · Cited by 2
“Cytokine support is a crucial factor allowing growth and survival of CML stem cells independent of BCR-ABL activity.[14] Thus, the cytokine microenvironment is an important determinant in BCR-ABL positive leukemia.”
BackgroundPagliaro, S., Desterke, C., Acloque, H., Chomel, J., de Souza, L. E. B., Hugues, P., Griscelli, F., Foudi, A., Griscelli, A. B., & Turhan, A. G. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.04.005 · Cited by 3
Rey-Caro, L. A., Pinzón, P., & Cruz-Rodríguez, N. (2020) · Salud UIS · doi:10.18273/revsal.v52n2-2020007 · Cited by 3
Gupta, P., Ashar, Y. V., Ashby, C. R., Lin, L., & Chen, Z. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00047-5 · Cited by 2
Discovery and design of dual inhibitors targeting Sphk1 and Sirt1
Liu, J., Zhao, H., He, L., Yu, R., & Cong-min, K. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05551-2 · Cited by 3
“The BCR22 and ABL9 form a fusion gene BCR/ABL in CML, which encodes the protein with constitutive tyrosine kinase activity [4].”
BackgroundANTI-TUMOR PROPERTY OF PLANT PROTEASE INHIBITOR ON HUMAN CHRONIC MYELOID LEUKEMIA CELLS
Bhattacharjee, N. (2022) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2022.140402 · Cited by 2
Cobaleda, C., Vicente‐Dueñas, C., Romero-Camarero, I., & Sánchez-García, I. (2012) · Wiley eBooks · doi:10.1002/9780470015902.a0020860.pub2 · Cited by 2
Warfvinge, R., Ulfsson, L. G., Dhapola, P., Safi, F., Sommarin, M. N. E., Soneji, S., Hjorth‐Hansen, H., Mustjoki, S. M., Richter, J., Thakur, R. K., et al. (2023) · eLife · doi:10.7554/elife.92074.1 · Cited by 3
Bica, V., Venafra, V., Massacci, G., Graziosi, S., Gualdi, S., Minnella, G., Sorà, F., Chiusolo, P., Brunetti, M. E., Napolitano, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.08.631869 · Cited by 2
New roles of STAT5 factors in chronic myeloid leukemia cell maintenance
Casetti, L. (2013) · theses.fr (ABES) · doi:10.70675/015b97bez21d7z47c6z92f5z071fb7a84bfc · Cited by 6
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Kesarwani, M., Kincaid, Z., & Azam, M. (2019) · Journal of Visualized Experiments · doi:10.3791/58194 · Cited by 1
PAI-1, hematopoietic stem cell, and chronic myeloid leukemia
Takahashi, N., & Harigae, H. (2025) · Biomedical Journal · doi:10.1016/j.bj.2025.100854 · Cited by 2
“CML leukemic stem cells CML LSCs, which are believed to be latent and quiescent in the bone marrow (BM) niche, are insensitive to TKIs [10,11].”
Unveiling the Advances in Protein Kinase: From Concept to Clinic
Singh, S. K., Paliwal, A., Kaushik, N., Sengar, M. S., & Negi, S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037406748250901214051 · Cited by 2
Thakur, R. K., & Karlsson, G. (2025) · Blood · doi:10.1182/blood.2025029011 · Cited by 3
Arif, K., Yousaf, M., & Khan, D. (2025) · BMC Cancer · doi:10.1186/s12885-025-15214-5 · Cited by 2
“Resistance to standard therapies in myeloid malignancies often involves the activation of alternative survival pathways [74], as demonstrated in AML models [75].”
Ikegami, A., Watanabe‐Takahashi, M., Shimasaki, K., Okuda, Y., Choda, M., Waku, T., Maru, Y., Deguchi, A., Nishino, Y., Miyazawa, A., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202504723r · Cited by 1
Li, F., Lin, J., Tian, P., Chen, H., Yang, Q., Guo, Q., Wang, J., He, Y., Chen, J., Hu, X., et al. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101421 · Cited by 1
Role of Sphingolipids in Hematological Malignancies: Myeloproliferative Disorders
Moorthi, S., & Luberto, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-20750-6_3 · Cited by 1
TGF-β Signaling in Leukemogenesis
Naka, K., & Hirao, A. (2013) · Springer eBooks · doi:10.1007/978-4-431-54409-8_8 · Cited by 1
Zhang, H. (2012) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/rqhp-dj51 · Cited by 1
THE ROLE OF JAK2 INHIBITORS IN THE MANAGEMENT OF CML: CAN WE REST THE CASE?
(2014) · Science Proceedings · doi:10.14800/sp.383 · Cited by 1
“Page 2 of 4 CML leukaemia stem cell (LSC) persistence is secondary to their insensitivity to TKI despite effective BCR-ABL kinase inhibition, suggesting that other pathways contribute to their survival [12-13] .”
BackgroundEffects of a Particular Heptapeptide on the IFN-α-Sensitive CML Cells
Yang, F., Chen, F., Wan, X.-X., Zhou, X., Zhou, M., Chen, H., Fu, J., & Zhang, D. (2015) · BioMed Research International · doi:10.1155/2015/325026 · Cited by 1
“It is evident that anymalignancy results frommultiple pathogenic factors, and the related studies showed that any anticancer molecule was not universally effective to tumors [20].”
BackgroundTraitement de la leucémie myéloïde chronique (LMC) en 2011
Tulliez, M. (2011) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(11)71002-4 · Cited by 1
New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance
Chorzalska, A. D., & Dubielecka, P. M. (2014) · Leukemia Supplements · doi:10.1038/leusup.2014.4 · Cited by 1
Lee, H.-R., Kim, M., Ha, G., Kim, S., Kim, S., & Kang, C. (2013) · Journal of Life Science · doi:10.5352/jls.2013.23.2.197 · Cited by 1
“Since it has been demonstrated that the primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro [20] and in vivo [5], and that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therap…”
BackgroundMetabolic Enzymes: The Novel Targets for Cancer Stem Cells
Li, J. L. P. (2014) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.1000197 · Cited by 1
“It will be important to dissect the function of SCD1 in LSCs.”
BackgroundInfluentialCharacterization and Targeting of Neoplastic Stem Cells in Ph + Chronic Myeloid Leukemia
Arock, M., Mahon, F., & Valent, P. (2015) · International Journal of Hematologic Oncology · doi:10.2217/ijh.15.16 · Cited by 1
Orphan drug development for targeting chronic myeloid leukemia stem cells
Xie, X., & Zhang, H. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1202820 · Cited by 1
The Response of Cancer Cell Populations to Therapies
Lindsay, D., Garvey, C. M., Mumenthaler, S. M., & Foo, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804310-3.00010-7 · Cited by 1
Okabe, S., Tauchi, T., Tanaka, Y., & Ohyashiki, K. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1312373 · Cited by 1
“However, resistance to ABL-TKI can develop in patients with chronic myeloid leukemia (CML) because of the presence of leukemia stem cells (LSCs) [2].”
BackgroundEt tu, E2F1? The assassins of CML stem cells
Krause, D. S. (2018) · Blood · doi:10.1182/blood-2018-02-833699 · Cited by 1
Baykal, S., & YALÇIN, P. (2021) · Journal of Basic and Clinical Health Sciences · doi:10.30621/jbachs.848797 · Cited by 1
The Biology and Pathogenesis of Chronic Myeloid Leukaemia
Shanmuganathan, N., Chereda, B., & Melo, J. V. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-71913-5_2 · Cited by 1
Zheng, X., Hua, S., Zhao, H., Gao, Z., & Cen, D. (2022) · Oncology Letters · doi:10.3892/ol.2022.13242 · Cited by 1
“…role in the development of CML. Tyrosine kinase inhibitors (TKIs) are able to induce remis‑ sion and improve survival in patients with CML; however, they are unable to eliminate leukemia stem cells (LSCs), as these cells do not depend on the kinase activity of BCR‑ABL oncoprotein for survival (8).”
Pearson, S., Whetton, A. D., & Pierce, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266298 · Cited by 1
Brown, G., & Ceredig, R. (2018) · MDPI eBooks · doi:10.3390/books978-3-03897-275-4 · Cited by 1
Laperrousaz, B. (2015) · theses.fr (ABES) · doi:10.70675/a5377ea8z83c9z4533z862cz975a6a065202 · Cited by 4
Fovez, Q. (2021) · theses.fr (ABES) · doi:10.70675/d86bb64bz9728z4f39z8e97zcb795508f29e · Cited by 1
Warfvinge, R., Ulfsson, L. G., Dhapola, P., Safi, F., Sommarin, M. N. E., Soneji, S., Hjorth‐Hansen, H., Mustjoki, S. M., Richter, J., Thakur, R. K., et al. (2024) · eLife · doi:10.7554/elife.92074.3.sa3 · Cited by 1
PAI-1 inhibitors, its potential and clinical application
Takashi, D. A. N., & MIYATA, T. (2015) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.26.310
Irvine, D. A. (2013) · Enlighten: Theses (The University of Glasgow)
Smith, B. D., & Cho, E. (2012) · Wiley eBooks · doi:10.1002/9781118464557.ch42
Analysis of Leukemogenic Gene Products in Hematopoietic Progenitor Cells
Schanda, J., Henschler, R., Grez, M., & Wichm, C. (2011) · InTech eBooks · doi:10.5772/26242 · Cited by 1
“Therefore, lifelong treatment of CML patients with tyrosine kinase inhibitors is necessary (Corbin et al., 2011; Diamond & Melo, 2011).”
BackgroundReichle, A., & Hahn, J. (2013) · Springer eBooks · doi:10.1007/978-94-007-6866-6_10
Functional Modeling of Genes Upregulated in Chronic Myeloid Leukemia
Hansen, N. (2013) · Lund University Publications (Lund University)
仲, 一. (2013) · PubMed
Sequence analysis of the NUMB gene in chronic myeloid leukaemia patients
Oberender, C. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-13110
Zhaleyko, I. O., Bilko, D., Dyagil, I., & Bilko, N. (2014) · Visnyk of Dnipropetrovsk University Biology medicine · doi:10.15421/021420
Minami, Y., & Naoe, T. (2012) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.s8-001
“However, several mathematical models and ex-vivo examinations suggested that imatinib (IM) therapy does not eradicate CML stem cells [3,8,12-14].”
BackgroundTerapia przewlekłej białaczki szpikowej – teraźniejszość i wyzwania na przyszłość
Głodkowska‐Mrówka, E., & Stokłosa, T. (2012) · Acta Haematologica Polonica · doi:10.1016/s0001-5814(12)34001-2
Suknuntha, K., Ishii, Y., Hu, K., Wang, J., Swanson, S. A., Stewart, R. M., Thomson, J. L., & Slukvin, I. I. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.05.066
Zhang, H. (2012) · Digital Commons-TMC (Texas Medical Center)
DNA Microarray Assay Helps to Identify Functional Genes Specific for Leukemia Stem Cells
Zhang, H., & Li, S. (2013) · Dataset Papers in Science · doi:10.1155/2013/520285
“Although increasing evidence demonstrated that CML stem cells utilize signaling pathways that are independent of BCRABL kinase activity for their maintenance and survival [11, 12], the underlying molecular mechanisms remain unclear.”
BackgroundNaturwissenschaften, F., & Fischer-Bosch-Institut, M. (2011)
Dixon, A. S. (2014) · J. Willard Marriott Library · doi:10.26053/0h-6t82-gxg0
Molecular Mechanisms of CML Stem Cell Maintenance
Hirao, A., Tadokoro, Y., & Ueno, M. (2015) · Springer eBooks · doi:10.1007/978-4-431-55714-2_2
Leukemic and Lymphoid Stem Cells
Becker, M. W., & O’Dwyer, K. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_13
Increasing sensitivity to drugs in leukemias by modulation of microRNA expression
Teixeira, H. L. P. S. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/7pvr-j630 · Cited by 1
Diachenko, M. V., Борбуляк, І., Bilko, D., Перехрестенко, Т. П., Tretyak, N. M., Dyagil, I., & Bilko, N. (2012) · Visnyk of Dnipropetrovsk University Biology medicine · doi:10.15421/021228
“Проте клінічні дослідження не підтвердили очікувані результати лікування із застосуванням Іматинібу через обмежену ефективність цього препарату щодо стовбурових клітин, що перебувають у стані спокою, а також індивідуальну варіабельність відповіді на терапію [3].”
Where are we going with CML research?
Perrotti, D. (2012) · Leukemia Supplements · doi:10.1038/leusup.2012.26
Cancer Stem Cells and Tumor Radioresistance
Chaudhuri, A. A., Binkley, M. S., & Diehn, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_18
Kaeda, J., Ringel, F., Oberender, C., Gresse, M., Amini, L., Schwarz, M., Dörken, B., & le Coutre, P. (2016) · Acta Haematologica · doi:10.1159/000445097
Hupfeld, T. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1664
(2013) · CRC Press eBooks · doi:10.1201/b14587-17
Rad52 DNA binding activity can be targeted to eliminate CML stem cells
Morales, K. (2012) · TUScholarShare (Temple University)
Ferreira, A. F. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2012.tde-31102014-152954
Lin, H. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0306413
Defining the Mode of Medulloblastoma Growth using the Ptch1 Heterozygous Mouse Model
Vanner, R. J. (2015) · TSpace (University of Toronto)
Metadata
- Authors
- Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Oregon Health & Science University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 396-409
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3007128
- OpenAlex
- W2122224021
- Cited by
- 765
- References
- 47
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 32 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 66 · 2016: 53 · 2015: 51 · 2014: 67 · 2013: 76 · 2012: 66
- FWCI
- 36.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- T.J. Martell Foundation
- Leukemia and Lymphoma Society
- National Heart, Lung, and Blood Institute (R01HL082978, HL082978-01)
- National Cancer Institute (R37CA065823)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib, BCR-ABL, leukemia stem cells, disease persistence, drug resistance, stem cell survival, CD34+CD38- cells, CD133, progenitor cells, oncogene addiction
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Models, Biological, Piperazines, Pyrimidines, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Cytokines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Cell Proliferation, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.